Abstract
Aims: Viral infections have been implicated in the development of Parkinson disease (PD). It has been observed that the presence of SARS-CoV-2 in dopaminergic cells can expedite the degeneration process and potentially exacerbate symptoms. The objective of this study was to assess the impact of the COVID-19 pandemic on individuals with PD.
Methods: A total of 60 patients were enrolled in the study. The severity of the disease was assessed using the using the Unified Parkinson's Disease Rating Scale (UPDRS), while the stage of the disease was determined using modified Hoehn &Yahr Rating Scale (m HYRS). Various measures were taken to evaluate the patients’ well-being, including the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Parkinson's Disease Quality of Life Questionnaire (PDQ-39), and Impact of Events Scale (IES-R) scores. The researchers also recorded the UPDRS scores, levodopa equivalent doses (LED), and BMI of the patients before and after the lockdown period. Subsequently, the collected data were compared to identify any significant changes.
Results: The difference in UPDRS, LED and BMI of the patients before and after the lockdown was statistically significant (p<0.05). Furthermore, there was a significant increase in UPDRS motor score, BAI, and PDQ-39 values among female patients compared to male patients (p<0.05). Comparing patients with and without COVID-19 infection, it was observed that patients who had contracted COVID-19 demonstrated a statistically significant increase in m HYRS and UPDRS motor scores, and PDQ-39 values after the lockdown (p<0.05). To assess the impact of various factors on the quality of life, multiple linear regression analysis was performed. The analysis revealed that COVID-19-positive patients and female patients experienced a more pronounced effect on their quality of life (p<0.05). Moreover, quality of life was found to be affected by disease stage, depression, anxiety, the IES-R scores increase, as well as by deteriorating sleep quality (p<0.05).
Conclusion: During the COVID-19 pandemic, PD patients experienced a worsening of clinical symptoms and increased treatment requirements. Furthermore, their quality of life was negatively affected, particularly among females and those who contracted COVID-19 infection. It is crucial to develop supportive treatment strategies targeting neuropsychological symptoms, as these could greatly contribute to the overall management and well-being of PD patients.
Keywords
References
- Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020; 91(8):795-808.
- Banerjee S, Mukherjee A, Bhattacharyya B, Mohanakumar KP, Biswas A. Quality of life and concerns of Parkinson's disease patients and their caregivers during COVID-19 pandemic: an Indian study. Ann Indian Acad Neurol. 2022;25(4):676-682.
- Cavallieri F, Fioravanti V, Bove F, et al. COVID-19 and parkinsonism: a critical appraisal. Biomolecules. 2022;12(7):970.
- Sulzer D, Antonini A, Leta V, et al. COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis. 2020;6:18.
- Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson’s disease patients affected by COVID-19. Mov Disord. 2020;35(6):905-908
- Tulisiak CT, Mercado G, Peelaerts W, Brundin L, Brundin P. Can infections trigger alpha-synucleinopathies?. Prog Mol Biol Transl Sci. 2019;168:299-322.
- Shalash A, Roushdy T, Essam M, et al. Mental health, physical activity, and quality of life in Parkinson's disease during COVID-19 pandemic. Mov Disord. 2020;35(7):1097-1099
- van der Heide A, Meinders MJ, Bloem BR, Helmich RC. The impact of the COVID-19 pandemic on psychological distress, physical activity, and symptom severity in Parkinson's disease. J Parkinsons Dis. 2020;10(4):1355-1364.
- Duan L, Zhu G. Psychological interventions for people affected by the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):300-302.
- Prasad S, Holla VV, Neeraja K, et al. Parkinson's disease and COVID-19: perceptions and implications in patients and caregivers. Mov Disord. 2020;35(6):912-914.
- Suzuki K, Numao A, Komagamine T, et al. Impact of the COVID-19 pandemic on the quality of life of patients with Parkinson's disease and their caregivers: a single-center survey in Tochigi prefecture. J Parkinsons Dis. 2021;11(3):1047-1056.
- Xia Y, Kou L, Zhang G, et al. Investigation on sleep and mental health of patients with Parkinson's disease during the Coronavirus disease 2019 pandemic. Sleep Med. 2020;75:428-433.
- Cilia R, Bonvegna S, Straccia G, et al. Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study. Mov Disord. 2020;35(8):1287-1292.
- Luis-Martínez R, Di Marco R, Weis L, et al. Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown. BMC Neurol. 2021;21:332.
- Dahodwala N, Shah K, He Y, et al. Sex disparities in access to caregiving in Parkinson disease. Neurology. 2018;90(1):48–54.
- Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819–824.
- Lee JJ, Ham JH, Lee PH, Sohn YH. Gender differences in age-related striatal dopamine depletion in Parkinson's disease. J Mov Disord. 2015;8(3):130-135. doi:10.14802/jmd.15031
- Balzer-Geldsetzer M, Klotsche J; LANDSCAPE Consortium, Dodel R, Riedel O. Quality of life in a German cohort of Parkinson's patients assessed with three different measures. J Neurol. 2018;265(11):2713-2722.
Abstract
References
- Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020; 91(8):795-808.
- Banerjee S, Mukherjee A, Bhattacharyya B, Mohanakumar KP, Biswas A. Quality of life and concerns of Parkinson's disease patients and their caregivers during COVID-19 pandemic: an Indian study. Ann Indian Acad Neurol. 2022;25(4):676-682.
- Cavallieri F, Fioravanti V, Bove F, et al. COVID-19 and parkinsonism: a critical appraisal. Biomolecules. 2022;12(7):970.
- Sulzer D, Antonini A, Leta V, et al. COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis. 2020;6:18.
- Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson’s disease patients affected by COVID-19. Mov Disord. 2020;35(6):905-908
- Tulisiak CT, Mercado G, Peelaerts W, Brundin L, Brundin P. Can infections trigger alpha-synucleinopathies?. Prog Mol Biol Transl Sci. 2019;168:299-322.
- Shalash A, Roushdy T, Essam M, et al. Mental health, physical activity, and quality of life in Parkinson's disease during COVID-19 pandemic. Mov Disord. 2020;35(7):1097-1099
- van der Heide A, Meinders MJ, Bloem BR, Helmich RC. The impact of the COVID-19 pandemic on psychological distress, physical activity, and symptom severity in Parkinson's disease. J Parkinsons Dis. 2020;10(4):1355-1364.
- Duan L, Zhu G. Psychological interventions for people affected by the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):300-302.
- Prasad S, Holla VV, Neeraja K, et al. Parkinson's disease and COVID-19: perceptions and implications in patients and caregivers. Mov Disord. 2020;35(6):912-914.
- Suzuki K, Numao A, Komagamine T, et al. Impact of the COVID-19 pandemic on the quality of life of patients with Parkinson's disease and their caregivers: a single-center survey in Tochigi prefecture. J Parkinsons Dis. 2021;11(3):1047-1056.
- Xia Y, Kou L, Zhang G, et al. Investigation on sleep and mental health of patients with Parkinson's disease during the Coronavirus disease 2019 pandemic. Sleep Med. 2020;75:428-433.
- Cilia R, Bonvegna S, Straccia G, et al. Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study. Mov Disord. 2020;35(8):1287-1292.
- Luis-Martínez R, Di Marco R, Weis L, et al. Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown. BMC Neurol. 2021;21:332.
- Dahodwala N, Shah K, He Y, et al. Sex disparities in access to caregiving in Parkinson disease. Neurology. 2018;90(1):48–54.
- Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819–824.
- Lee JJ, Ham JH, Lee PH, Sohn YH. Gender differences in age-related striatal dopamine depletion in Parkinson's disease. J Mov Disord. 2015;8(3):130-135. doi:10.14802/jmd.15031
- Balzer-Geldsetzer M, Klotsche J; LANDSCAPE Consortium, Dodel R, Riedel O. Quality of life in a German cohort of Parkinson's patients assessed with three different measures. J Neurol. 2018;265(11):2713-2722.
Details
| Primary Language | English |
|---|---|
| Subjects | Neurology and Neuromuscular Diseases |
| Journal Section | Original Article |
| Authors | |
| Early Pub Date | July 28, 2023 |
| Publication Date | July 30, 2023 |
| Published in Issue | Year 2023 Volume: 6 Issue: 4 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
|
|
|
| |
|
|
|
|
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
|
|
|
|
|
|
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.